Financing round led by Fidelity and T. Rowe Price funds underscores vast opportunities to bring Inscripta’s technology to the broader bioeconomy.

Soufflé Therapeutics has closed an oversubscribed $135 million Series B round led by Juvia Group. New investors include TCG Crossover Management, BB Biotech, Fidelity Management & Research Company, Balyasny Asset Management, and a sovereign wealth fund. Existing backers such as Amgen Ventures, ARCH Venture Partners, and Temasek also took part. The RNA therapies company will use the money to move its three lead programs into clinical studies. They target facioscapulohumeral muscular dystrophy (FSHD), heart failure with reduced ejection fraction, and muscle and metabolic disorders. It will also advance its pipeline in other cell types and tissues. Its REMEDY (Receptor Mediated Delivery) engine delivers oligonucleotide therapies to specific cells outside the liver. "This exceptional group of investors" backs the engine's potential, said chief executive officer Amir Nashat.

Fidelity's Jurrien Timmer predicts Q3 earnings growth could reach 30% to 35% if recent quarters' typical post-reporting bounce repeats. Despite trailing earnings being up 28% and forward earnings expected to rise another 20%, the market's trailing price-to-earnings multiple has fallen 10% year-over-year. Timmer, Fidelity's Director of Global Macro, notes that investors historically don't pay top multiples for peak earnings growth. Bloomberg data shows Q2 2026 growth estimates at 34% and Q1 2026 at 29%, well above the 11% to 15% posted from Q4 2024 through Q3 2025. The S&P 500 has already reached a record high above 7,800. Schwab's Kevin Gordon warns that a single mega-cap capital expenditure miss could disrupt earnings, noting AI stocks now carry much of the index.